MFA Wealth Advisors LLC Takes Position in Pfizer Inc. (NYSE:PFE)

MFA Wealth Advisors LLC acquired a new stake in shares of Pfizer Inc. (NYSE:PFE) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 1,054 shares of the biopharmaceutical company’s stock, valued at approximately $29,000.

Other institutional investors also recently bought and sold shares of the company. Diversified Portfolios Inc. acquired a new position in Pfizer during the 2nd quarter valued at about $204,000. Prossimo Advisors LLC purchased a new position in shares of Pfizer in the second quarter worth $678,000. Atria Wealth Solutions Inc. grew its holdings in shares of Pfizer by 10.7% during the second quarter. Atria Wealth Solutions Inc. now owns 550,095 shares of the biopharmaceutical company’s stock valued at $15,392,000 after buying an additional 53,295 shares during the last quarter. Aaron Wealth Advisors LLC lifted its position in Pfizer by 41.2% during the 2nd quarter. Aaron Wealth Advisors LLC now owns 11,698 shares of the biopharmaceutical company’s stock worth $327,000 after acquiring an additional 3,411 shares during the period. Finally, Sloy Dahl & Holst LLC grew its stake in Pfizer by 12.5% during the 2nd quarter. Sloy Dahl & Holst LLC now owns 8,342 shares of the biopharmaceutical company’s stock valued at $233,000 after purchasing an additional 925 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. Morgan Stanley raised their price objective on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 2nd. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. StockNews.com raised shares of Pfizer from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Monday. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $36.00 price target (up from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Eight analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Pfizer currently has an average rating of “Moderate Buy” and an average price target of $34.54.

Pfizer Price Performance

Shares of Pfizer stock traded up $0.12 during trading hours on Wednesday, reaching $29.02. 16,719,696 shares of the company’s stock were exchanged, compared to its average volume of 39,231,648. The business has a fifty day moving average of $28.80 and a two-hundred day moving average of $27.94. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65. The company has a market capitalization of $164.42 billion, a P/E ratio of -483.58, a price-to-earnings-growth ratio of 1.00 and a beta of 0.69. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $37.15.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The business had revenue of $13.28 billion for the quarter, compared to analysts’ expectations of $12.96 billion. During the same period in the previous year, the firm posted $0.67 EPS. The business’s revenue for the quarter was up 2.1% compared to the same quarter last year. As a group, research analysts predict that Pfizer Inc. will post 2.68 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, July 26th will be issued a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.79%. The ex-dividend date of this dividend is Friday, July 26th. Pfizer’s dividend payout ratio is currently -2,800.00%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.